The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fatigue, cognitive deficits, and depression are frequently reported but often undertreated symptoms that can profoundly affect daily life in patients with primary brain tumors (PBTs). To evaluate the effects of the psychostimulant modafinil on fatigue, depression, health-related quality of life (HRQOL), and cognitive functioning in PBT patients, we performed a multicenter, double-blind placebo-controlled crossover trial. METHODS: Patients randomly received either 6 weeks of treatment with modafinil (up to 400 mg/day) or 6 weeks with placebo. After a 1-week washout period, the opposite treatment was provided. Assessments took place at baseline and immediately after the first and second condition. Patients completed self-report questionnaires on fatigue (Checklist Individual Strength [CIS]), depression (Center for Epidemiologic Studies Depression Scale [CES-D]), HRQOL (Short-Form Health Survey [SF-36]), and self-perceived cognitive functioning (Medical Outcomes Study [MOS]). They also underwent comprehensive neurocognitive testing. RESULTS: In total, 37 patients participated. Relative to baseline, patients reported lower fatigue severity (CIS) and better motivation (CIS) in both the modafinil (P = .010 and P = .021, respectively) and the placebo condition (P < .001 and P = .027, respectively). The same held for physical health (SF-36 Physical Component Summary score; P = .001 and P = .008, respectively), working memory (P = .040 and P = .043), and information processing capacity (P = .036 and P = .040). No improvement in depressive symptoms was found in either condition. CONCLUSIONS: Modafinil did not exceed the effects of placebo with respect to symptom management. Patient accrual was slow, and relatively many patients dropped out during the trial, due mostly to side effects. Other, preferably nonpharmacologic intervention studies should be considered to improve symptom management of PBT patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring Functioning and Well-Being: The Medical Outcomes Study Approach
Stewart, A., & Ware, J. (1992) · doi:10.7249/cb361 · Cited by 2,689
Aaronson, N. K., Muller, M., Cohen, P. D. A., Essink-Bot, M.-L., Fekkes, M., Sanderman, R., Sprangers, M. A. G., te Velde, A., & Verrips, E. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00097-3 · Cited by 2,276
Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., & Küffner, R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.8922 · Cited by 912 · cited 1×
“For depressive symptoms, nonpharmacologic intervention studies in this patient population are also still scarce, although many therapeutic interventions already exist for different cancer patient populations.(56) Because of their unique symptom pattern with neurological and cognitive sequelae, PBT patients are not eas…”
BackgroundNonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
Kuczenski, R., & Segal, D. S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052032.x · Cited by 623 · cited 1×
“It inhibits dopamine and norepinephrine uptake and increases concentrations of these neurotransmitters in the brain.(37) It targets primarily the prefrontal cortex.”
BackgroundPelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1015728825642 · Cited by 362 · cited 1×
“All of these symptoms have a large impact on the everyday life of patients and may lead to a significant decrease in health-related quality of life (HRQOL).(8) It is suggested that effective treatment of these symptoms may increase HRQOL,(9) although an optimal strategy to reach this goal has not been defined yet.”
BackgroundGehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., & Wefel, J. S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0723-1 · Cited by 161 · cited 4×
“et al.(39) reported beneficial effects of both modafinil and methylphenidate for patient-reported measures of fatigue, mood, and HRQOL as well as for objective neuropsychological testing.”
BackgroundInfluentialBerridge, C. W., & Devilbiss, D. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.023 · Cited by 160
JONES, D. E. J., & NEWTON, J. L. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03223.x · Cited by 114
Cited by
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationCancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment
Fabi, A., Bhargava, R., Fatigoni, S., Guglielmo, M., Horneber, M., Roila, F., Weis, J., Jordan, K., & Ripamonti, C. I. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.016 · Cited by 570
European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
Pace, A., Dirven, L., Koekkoek, J. A. F., Golla, H., Fleming, J., Rudà, R., Marosi, C., Rhun, E. L., Grant, R., Oliver, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30345-5 · Cited by 297
Self-citationSymptom management and quality of life in glioma patients
Boele, F. W., Klein, M., Reijneveld, J. C., Verdonck-de Leeuw, I. M., & Heimans, J. J. (2014) · CNS Oncology · doi:10.2217/cns.13.65 · Cited by 107
Self-citationAn Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil
Murillo-Rodríguez, E., Barciela Veras, A., Barbosa Rocha, N., Budde, H., & Machado, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00374 · Cited by 91
Metadata
- Authors
- Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., Taphoorn, M. J. B., Reijneveld, J. C., & Klein, M.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-07
- Volume
- 15
- Issue
- 10
- Pages
- 1420-1428
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2146597482
- Cited by
- 134
- References
- 10
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. https://app.cochat.ai/papers/10.1093/neuonc/not102
- The paper
- Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., Taphoorn, M. J. B., Reijneveld, J. C., & Klein, M. (2013). The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro-Oncology. https://doi.org/10.1093/neuonc/not102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.